Prognostic significance of nm23 protein expression in malignant melanoma. An immunohistochemical study

Melanoma Research

Volumn 7, Issue 2, 1997, Pages 121-128

  Van Den Oord, J J ^a   Maes, A ^a   Stas, M ^a   Nuyts, J ^a   De Wever, I ^a   De Wolf Peeters, C ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

melanoma; nm23, immunohistochemistry; prognosis

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; NUCLEOSIDE DIPHOSPHATE KINASE;

ADULT; AGED; ARTICLE; BLUE NEVUS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL NEVUS; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEVUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0030964938     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199704000-00006     Document Type: Article

References (44)

1. Bishop JM. Molecular themes in oncogenesis. Cell 64: 235-248: 1991.
2. Steeg PS, Bevilacqua G, Kopper, L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumour metastatic potential. J Natl Cancer Inst 1988; 80: 200-204.
3. Rosengard AM, Krutsch HC, Shearn A, Biggs JR, Barker E, Margulies IM, et al. Reduced nm23/awd protein in tumour metastasis and aberrant Drosophila development. Nature 1980; 342: 177-180.
4. Stahl JA, Leone A, Rosengard AM, Porter L, King CR, Steeg PS. Identification of a second human nm23 gene, nm23-H2. Cancer Res 1991; 51: 445-449.
5. Backer JM, Mendola CE, Kovesdi I, Fairhurst JL, O'Hara B, Eddy Jr RL, et al. Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2. Oncogene 1993; 8: 497-502.
6. Gilles A-M, Presecan E, Vonica A, Lascu I. Nucleoside diphosphate kinase from human erythrocytes. Structural characterisation of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem 1991; 266: 8784-8789.
7. Steeg PS, Vevilacqua G, Pozzatti R, Liotta LA, Sobel ME. Altered expression of nm23, a gene associated with low tumour metastatic potential, during adenovirus 2 E1a inhibition of experimental metastasis Cancer Res 1988; 48: 6550-6554.
8. Leone A, Flatow U, King RC, Sandeen MA, Margulies IMK, Liotta LA, et al. Reduced tumour incidence, metastatic potential, and cytokine responsiveness of nm-23 transfected melanoma cells. Cell 1991; 65: 25-35.
9. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis. An imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
10. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 nRNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histophathological indicators of high netastatic potential. Cancer Res 1989; 49: 5185-5190.
11. Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lenjnard TWJ. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst 1991; 83: 281-285.
12. Hirayama R, Sawai S, Takagi Y, Mishima Y, Kimura N, Shimada N, et al. Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside disphosphate kinase) and good prognosis in human breast cancer. J Natl Cancer Inst 1991; 83: 1249-1252.
13. Barnes R, Masood S, Barker E, Rosengard AM, Coggin DL, Crowell T, et al. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 1991; 139: 245-250.
14. Royds J, Stephenson T, Rees R, Shorthouse A, Silcocks D. nm23 gene product in in situ and invasive human breast cancer. J Natl Cancer Inst 1993.
15. Sastre-Garau X, Lacombe ML, Jouve M, Veron M, Magdelenat H. Nucleoside diphosphate kinase/nm23 expression in breast cancer. Lack of correlation with lymph node metastasis. Int J Cancer 1992; 50: 533-538.
16. Nakayama T, Ohtsuru A, Nakao K, Shima M, Nakato K, Watanabe K, et al. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst 1992; 84: 1349-1453.
17. Haut M, Steeg PS, Wilson JKV, Markowitz SD. Indication of nm23 gene expression in human colonie neoplasms and equal expression in colon tumours of high and low metastatic potential. J Natl Cancer Inst 1991; 83: 712-716.
18. Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and n-myc gene amplification. J Clin Invest 1991; 88: 341-345.
19. Lacombe ML, Sastre-Garau X, Lascu I, Vonica A, Wallet V, Thiery JP, et al. Overexpression of nucleoside diphosphate kinase (nm23) in solid tumours. Eur J Cancer 1991; 27: 1302-1307.
20. Holm R, Tanum G. Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. Virchows Arch 1996; 428: 85-89.
21. Steeg PS, Cohn KH, Leone A. Tumour metastasis and nm23, current concepts. Cancer Cells 1991; 3: 257-262.
22. Welch DR, Chen P, Miele ME, McGary CT, Bower JM, Stanbridge EJ, et al. Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 1994; 9: 255-262.
23. Florenes VA, Aamdal S, Myklebost O, Maelandsmo M, Bruland OS, Rodstad O. Levels of nm23 RNA in metastatic malignant melanomas. Inverse correlation to disease progression. Cancer Res 1992; 52: 6088-6091.
24. Xerri L, Grob JJ, Battyani Z, Gouvernet J, Hassoun J, Bonerandi JJ. NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br J Cancer 1994; 70: 1224-1228.
25. Caligo MA, Grammatico P, Cipollini G, Varesco L, Del Porto G, Bevilacqua G. A low NM23.H1 gene expression identifying high malignancy human melanomas. Melanoma Res 1994; 4: 179-184.
26. Elder DE, Murphy G. Melanocytic tumours of the skin. Atlas of Tumour Pathology. Washington. American Registry of Pathology, Armed Forces Institute of Pathology, 1990; 155-161.
27. Nakopoulou LL, Constantdinides CA, Tzonou A, Lazaris Ach, Zervas A, Dimopoulos CA. Immunohistochemical evaluation of nm23-H1 gene product in transitional cell carcinoma of the bladder. Histopathology 1996; 28: 429-435.
28. Keim D, Hailat N, Melhem K, Zhu XX, Lascu I, Veron M, et al. Proliferation-related expression of p19/nm23 nucleoside diphosphate kinase. J Clin Invest 1992; 89: 919-924.
29. Caligo MA, Cipollini G, Fiore L, Calvo S, Basolo F, Collecchi P, et al. NM23 gene expression correlates with cell growth rate and S-phase. Int J Cancer 1995; 60: 837-842.
30. Bentley-Phillips C, Marks R. Cell division and metabolic activity of naevus cells. The relationship between anatomy and behaviour in moles. Br J Dermatol 1976; 94: 557-563.
31. Pierard GE, Pierard-Franchimont C. The proliferate activity of cells of malignant melanoma. Am J Dermatopathol 1984; 6 (Suppl. 1): 317-323.
32. Smolle J, Soyer HP, Kerl H. Proliferate activity of cutaneous melanocytic tumours defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol 1989; 11: 301-307.
33. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. bcl-2 Expression in human melanocytes and melanocytic tumours. Am J Pathol 1994; 145: 294-300.
34. Okabe-Kado J, Kasukabe T, Honma T, Hayashi M, Henzel W, Hozumi M. Identity of a differentiation inhibiting factor for mouse myeloid leukaemia cells with nm23/nucleoside diphosphate kinase. Bichem Biophys Res Commun 1992; 182: 987-994.
35. Tu P, Miyauchi S, Miki Y. Proliterale activities in Spitz nevus compared with melanocytic naevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate. Am J Dermatopathol 1993; 15: 311-314.
36. Zou M, Shi Y, Al-Sedairy S, Farid NR. High levels of nm23 gene expression in advanced stage of thyroid carcinomas. Br J Cancer 1993; 68: 385-388.
37. Aryee DNT, Stroebel T, Kos K, Salzer-Kuntschik M. nm23-H1/NDPK-A expression in Ewing tumours, paradoxical immunohistochemical reactivity and lack of prognostic significance. Int J Cancer 1995; 64: 104.
38. Mandai M, Konishi I, Koshiyama M, Komatsu T, Yamamoto S, Nanbu K, et al. Altered expression nm-23 H1 and c-erb B-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995; 75: 2523-2529.
39. Lee CS, Pirdas-Zivcic A. nm23-H1 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Pathology 1994; 26: 448-452.
40. Ozeki Y, Takishima K, Mamiya G. Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: association with tumour progression in Clara cell type. Jpn J Cancer Res 1994; 85: 840-846.
41. Stephenson TJ, Royds JA, Bleehen SS, Silcocks PB, Rees RC. Anti-metastatic nm23 gene product expression in keratoacanthoma and squamous cell carcinoma. Dermatology 1993; 187: 95-99 .
42. Bertheau P, De La Rosa A, Steeg PS, Merino MJ. NM23 protein in neoplastic and nonneoplastic thyroid tissues. Am J Pathol 1994; 145: 26-3225.
43. Postel EH, Berberich SJ, Flint SJ, Ferrone CA. Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumour metastasis. Science 1993; 261: 478-480.
44. Lazaris AC, Theodoropoulos GF, Aroni K, Saetta A, Davaris PS. Immunohistochemical expression of c-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995; 426: 461-467.